Axiom International Investors LLC DE reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 0.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 179,166 shares of the life sciences company’s stock after selling 924 shares during the period. Illumina accounts for approximately 1.9% of Axiom International Investors LLC DE’s investment portfolio, making the stock its 14th largest holding. Axiom International Investors LLC DE owned approximately 0.12% of Illumina worth $65,765,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. Moneta Group Investment Advisors LLC grew its stake in shares of Illumina by 2,670.0% during the second quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock worth $107,000 after purchasing an additional 9,345 shares during the period. Sun Life Financial INC grew its stake in shares of Illumina by 152.5% during the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock worth $111,000 after purchasing an additional 241 shares during the period. Highstreet Asset Management Inc. acquired a new stake in shares of Illumina during the third quarter worth $112,000. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Illumina by 3,192.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock worth $120,000 after purchasing an additional 415 shares during the period. Finally, Ancora Advisors LLC acquired a new stake in shares of Illumina during the third quarter worth $145,000. 91.60% of the stock is owned by institutional investors.
ILMN has been the subject of a number of analyst reports. ValuEngine cut Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Barclays lifted their price objective on Illumina from $350.00 to $370.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 24th. BidaskClub raised Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 1st. Morgan Stanley raised Illumina from an “underweight” rating to an “equal weight” rating and lifted their price objective for the stock from $210.00 to $320.00 in a research note on Tuesday, August 7th. Finally, Cowen lifted their price objective on Illumina from $315.00 to $400.00 and gave the stock a “positive” rating in a research note on Thursday, September 6th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Illumina currently has an average rating of “Buy” and an average price target of $330.94.
In other news, insider Francis A. Desouza sold 2,100 shares of the business’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $369.61, for a total value of $776,181.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Robert S. Epstein sold 1,346 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $345.14, for a total value of $464,558.44. Following the completion of the sale, the director now owns 7,139 shares in the company, valued at $2,463,954.46. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,408 shares of company stock worth $22,258,422. Corporate insiders own 0.54% of the company’s stock.
ILMN stock opened at $337.96 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. The stock has a market cap of $47.30 billion, a price-to-earnings ratio of 84.49, a price-to-earnings-growth ratio of 2.39 and a beta of 1.07. Illumina, Inc. has a 1-year low of $207.51 and a 1-year high of $372.61.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.26 by $0.26. The firm had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The company’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.11 earnings per share. Analysts predict that Illumina, Inc. will post 5.75 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/11/30/axiom-international-investors-llc-de-lowers-stake-in-illumina-inc-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Article: What are the economic characteristics of a bear market?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.